- NEWS AND VIEWS
Bioengineered ‘mini-colons’ shed light on cancer progression
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 629, 292-293 (2024)
doi: https://doi.org/10.1038/d41586-024-01018-3
References
Lorenzo-Martín, L. F. et al. Nature 629, 450–457 (2024).
Hanahan, D. & Weinberg, R. A. Cell 144, 646–674 (2011).
Clevers, H. Cell 165, 1586–1597 (2016).
Nikolaev, M. et al. Nature 585, 574–578 (2020).
Drost, J. et al. Nature 521, 43–47 (2015).
Barker, N. et al. Nature 457, 608–611 (2009).
Kozar, S. et al. Cell Stem Cell 13, 626–633 (2013).
Nicholson, A. M. et al. Cell Stem Cell 22, 909–918 (2018).
Competing Interests
N.R. is employed by Genentech, Inc. and owns shares of Roche. F.d.S.e.M. is an employee of Amgen and owns shares of Roche and Amgen.